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Abstract 
Breast cancer is the second most common type of cancer among women, with an estimated 2.8 
million diagnosed in the United States. Many cancers cannot be detected by their intrinsic 
vascular contrast, especially in their early stages. This necessitates the use of an exogenous 
contrast agent. Photoacoustic Imaging (PAI) and Fluorescence imaging (FI) are promising non-
invasive in vivo cancer diagnostic methods. To further improve the tumor to background 
contrast, researchers are investigating various exogenous contrast agents for PAI and 
fluorescence imaging that target tumor vasculature and hypoxia.  
This dissertation is structured into two main sections. In the first part, the evaluation of several 
novel porphyrin dyes has been presented as PAI contrast agents in direct comparison to the 
commonly used indocyanine green (ICG).  Imaging of a sub-mm target containing quinoline-
annulated porphyrin up to 2 cm depth in a tissue-like matrix exceeds the performance of imaging 
the similar target containing ICG, which suggests the use of quinoline-annulated porphyrins as 
potential contrast agents for cancer detection using PAI. The second part of the dissertation 
reports an investigation of the unsubstituted imidazole derivative as well as the 4-nitroimidazole 
ICG-conjugate for targeting tumor hypoxia. The performance of 4-nitroimidazole dye by 
imaging tumor cells in vitro and animals in vivo were validated, and the results with the 2-
nitroimidazole dye were compared, using the imidazole derivative as the reference. The results 
demonstrated the efficacy of 4-nitroimidazole-ICG as a hypoxia targeting fluorescence probe and 
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suggest the use of 4-nitroimidazole dye-conjugate as a hypoxia probe with a significant cost 
reduction in the synthesis.  
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Chapter 1 
Breast Cancer and Optical Imaging 
 
1-1 Introduction 
1-1.1 Overview 
Breast cancer is the second most common type of cancer, with an estimated 2.8 million 
diagnosed breast cancer patients in the United States. The mortality rate is estimated at 17% in 
the 232,340 patients diagnosed in 2013 [1]. This mortality rate can be drastically reduced by 
early detection, however many cancers cannot be detected by their intrinsic vascular contrast, 
especially in their early stages [2, 3]. This necessitates the use of an exogenous contrast agent. 
Different contrast agents such as nanoparticles, gold nanoparticles containing organic dyes such 
as ICG (indocyanine green) and porphysomes have been used [4-6]. Near-infrared (NIR) optical 
imaging distinguishes itself from other imaging modalities by its features such as non-ionizing 
radiation, noninvasive technology for imaging and quantifying vascularity, multimodal imaging, 
cost effectiveness and its ability for real time data acquisition. Near Infra-red imaging have better 
tissue penetration, less autofluorescence, and large Stokes shifts. Near-infrared fluorescence 
imaging and the use of nitroimidazoles as exogenous probes has received great attention because 
of their unique behavior in hypoxic environments owing to their high electron affinity [15-17]. 
Nonetheless, Photoacoustic Imaging (PAI) and Fluorescence imaging are promising non-
invasive in vivo diagnostic methods. PAI provides optical contrast at ultrasonic imaging 
resolution. To further improve the optical contrast, researchers are investigating various 
exogenous contrast agents for PAI and fluorescence imaging that target tumor vascularity with 
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appropriate tumor-specific ligands and target tumor hypoxia [7-10]. PAI has an advantage over 
other imaging modalities such as MRI and CT by its non-ionizing effect, the absence of 
radioactivity, and its combined high ultrasonic resolution and high optical contrast.  
This research focuses on the identification and evaluation of next generation novel 
contrast agents that may significantly enhance the effectiveness of PAI in early visualization of 
breast cancer. The overarching goal of this research is to increase the optical contrast in PAI and 
improve tumor hypoxia targeting using fluorescence imaging modality, to enable early detection 
of cancerous tumors resulting in decrease or morbidity and mortality in patients. 
 
1-1.2 Photoacoustic principle 
Photoacoustic phenomena was first described by Alexander Graham Bell in 1880 [12]. The lack 
of strong light sources caused further research on the application to cease soon after. With the 
development of lasers in the early 1970s, photoacoustic spectroscopy was revived. Lasers 
provided high intensity light at a tunable frequency, which allowed an increase in sound 
amplitude and sensitivity. The basic principle of the photoacoustic phenomena can be described 
as a chromophore or a particle absorbs a pulsed radiation energy, the absorbed energy is 
converted into heat and the temperature of the object increases. This rise in temperature causes a 
thermal expansion, generating an acoustic wave in the medium [11]. By detecting these acoustic 
waves using an ultrasound transducer and processing them using a beamforming algorithm, 
photoacoustic images are formed. PAI can reconstruct light absorption map inside the biological 
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tissue. The photoacoustic wave generation is described by the general photoacoustic equation 
[23]  
 (1) 
where p(r, t) denotes the acoustic pressure at location r and time t, vs denotes the speed of sound 
(∼1480 m/s in water), β denotes the thermal coefficient of volume expansion (∼4×10−4 K−1 for 
muscle), H is the heating function defined as the thermal energy converted per unit volume and 
per unit time; it is related to the optical absorption coefficient μa and fluence rate Φ by H = μaΦ 
and Cp [∼4000 J/(kg·K) for muscle] denote the specific heat capacity at constant pressure. The 
left-hand side of equation (1) describes the wave propagation, whereas the right-hand side 
represents the source term. For a short laser pulse that satisfies the assumption that the laser 
pulse duration is less than the acoustic confinement time, which is less than the thermal 
confinement time, the following thermal equation holds: 
, (2) 
where T denotes the temperature rise and Cv denote the specific heat capacity at constant 
volume. 
Using the forward solution, the general photoacoustic equation can be solved by the 
Green’s function approach which is defined as the response to a spatial and temporal impulse 
source term, assuming an infinite space, where no boundary exists 
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, (3) 
which represents an impulse diverging spherical wave, where r’ and t’ denote the source location 
and time, respectively. Applying the Green’s function approach, we get 
, (4) 
 
which represents the pressure in response to an arbitrary source. Here, κ denotes the isothermal 
compressibility. By substituting, simplifying and approximating the heat function Ht(t’)=δ(t’) we 
get 
, (5) 
which can be used to compute photoacoustic pressure generated by an arbitrarily heterogeneous 
optically absorbing object. 
1-1.3 Fluorescence Imaging 
In fluorescence imaging, photons are absorbed by a fluorescent molecule, and emits light 
(fluoresces) at a longer wavelength in order to return from its excited state to its ground energy 
state in a certain period of time. This emitted light can be captured with CCD (charge-couple 
device) camera or detectors, and the quality of the detection will rely mainly on the capacity to 
filtrate the emitted photons from the illumination light. The absorption of light is connected with 
  
 
 
 
5 
 
an electronic transition from the ground state to an excited stated of the molecule. The light 
passing through a layer of thickness d is attenuated and described as  
I(λ) = Io exp(-µad) = Io 10-ελ Cab d ,  (6) 
where I(λ) is the transmitted light intensity, Io is the incident intensity, ελ is the molar extinction 
coefficient and Cab is the concentration of the absorbing molecule [13]. In scattering samples, the 
absorbing coefficient µa and the scattering coefficient µs sums up. The molecule fluorescence 
intensity or quantum flux corresponds to the intensity equation 
  IF(λ) = Io [1 – 10-ελ Cab d ] ΦF 
Ω
π
 ,   (7) 
where ΦF is the fluorescence quantum yield and Ω the angle of detection of the isotropic 
fluorescence radiation. In case of thin samples such as cells or biopsies with thickness in the 
micrometer range the fluorescence intensity equation can be approximated as 
IF(λ) = Io ln10-ελ Cab d ΦF 
Ω
π
 ,   (8) 
which implies that fluorescence intensity is proportional to the concentration and the 
fluorescence quantum yield of the absorbing molecule. 
The fluorescence quantum yield (ΦF) is the ratio of photons absorbed to photons emitted 
through fluorescence. In other words the quantum yield gives the probability of the excited state 
being deactivated by fluorescence rather than by another, non-radiative mechanism. The most 
reliable method for recording the quantum yield is the comparative method [14], which involves 
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the use of well characterized standard samples with known fluorescence quantum yield values. 
Essentially, solutions of the standard and test samples with identical absorbance at the same 
excitation wavelength can be assumed to be absorbing the same number of photons. Hence, a 
simple ratio of the integrated fluorescence intensities of the two solutions (recorded under 
identical conditions) will yield the ratio of the quantum yield values based on the following 
equation  
,   (9) 
where the subscripts ST and X denote standard and test respectively, Φ is the fluorescence 
quantum yield, Grad the gradient of integrated fluorescence intensity versus absorbance, and η 
the refractive index of the solvent used. 
1-1.4 Tumor angiogenesis 
Tumor angiogenesis is the proliferation of a network of blood vessels that penetrates into 
cancerous growths, supplying nutrients and oxygen, and removing waste products. This process 
starts with cancerous tumor cells releasing signaling molecules to surrounding normal host tissue 
which in turn activates certain genes in the host tissue which make proteins to encourage growth 
of new blood vessels. Furthermore, the increased demand of oxygen due to the hyper metabolism 
of tumors reduces the oxygen saturation of the hemoglobin content within the surrounding tissue 
as seen in Figure 1-1. Multi-wavelength optical imaging reveals both angiogenesis and hyper 
metabolism, both of which are important hallmarks of tumor proliferation, growth, and 
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metastasis [18-19]. Angiogenesis is considered one of the fastest growing fields in biomedical 
research, and advances in our basic understanding of this process and its application have been 
rapid.  
Tumor hypoxia leads to an increased level of regulatory transcription factors such as 
hypoxia inducible factor (HIF-1α) to upregulate the expression of genes associated with tumor 
initiation, malignant progression, metastasis and resistance to chemotherapy and radiotherapy 
[20-22,26]. However, the effects of angiogenesis remain controversial. HIF-1α protein 
expression is similar in normoxic and hypoxic conditions but tends to stabilize in hypoxic 
environments. HIF-1α combines with HIF-1β and activates several HIF-1 target gene to express 
proteins, such as VEGF (Vascular endothelial growth factor), which is a significant protein 
involved in angiogenesis.[24,27] Hence, many studies indicate that most solid tumors, regardless 
of site of origin, contain hypoxic regions of biological and clinical significance. [25] 
 
  
 
 
 
8 
 
Figure 1-1 The vasculature structural differences of normal and malignant tissues. Normal tissues have 
relatively uniform and well-ordered blood vessels that are sufficiently close together to oxygenate all of 
the tissue, blood vessels in tumors are tortuous, have incomplete vessel walls, have sluggish and irregular 
blood flow, and have regions of hypoxia between the vessels. (Image from Ref. 20) 
 
1-1.5 Statement of work 
The overarching goal of this research is to increase the optical contrast in PAI and improve 
tumor hypoxia targeting using fluorescence imaging modality, to enable early detection of 
cancerous tumors resulting in decrease or morbidity and mortality in patients. This dissertation is 
structured into two main sections. Chapter 2 introduces the evaluation of several novel porphyrin 
dyes as PAI contrast agents in direct comparison to the commonly used indocyanine green (ICG) 
and blood.  Imaging of a sub-mm target containing quinoline-annulated porphyrin up to 2 cm 
depth in a tissue-like matrix exceeds the performance of imaging the similar target containing 
ICG, which suggests the use of quinoline-annulated porphyrins as potential contrast agents for 
cancer detection using PAI. Chapter 3 of the dissertation reports an investigation of the 
unsubstituted imidazole derivative as well as the 4-nitroimidazole ICG-conjugate for targeting 
tumor hypoxia using fluorescence imaging modality. The performance of 4-nitroimidazole dye 
has been validated by imaging tumor cells in vitro and animals in vivo and compared the results 
with the 2-nitroimidazole dye, using the imidazole derivative as the reference. Histology images 
of tumor stained sections was performed to confirm hypoxic condition of mice groups.   
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Chapter 2 
Porphyrin-derived photoacoustic contrast agents 
 
2-1 Introduction 
Photoacoustic imaging (PAI) is a non-invasive biomedical imaging modality that combines 
optical and ultrasound imaging in such a way that its key characteristics are superior to each of 
the component imaging techniques.[1-4] The absorption of a light pulse by a chromophore 
causes a rapid and transient rise in temperature (in the order of mK), leading to a localized 
thermal-elastic expansion. As a laser beam pulsed in the nanosecond range is scanned through an 
object to be imaged, the emitted ultrasonic wave profile is acquired with standard ultrasonic 
transducers. The data are used to reconstruct 2D or 3D optical absorption maps. PAI combines 
the advantages of high optical contrast and ultrasound (sub-mm) spatial resolution.[1, 5-7] 
Using the high optical absorption of the endogenous chromophore hemoglobin, PAI 
proved itself as a powerful tool for imaging the blood content of, for instance, the vascular 
network of cancers in rodent brains or ovary tissues, in mesoscopic biological objects, or present 
in whole animals.[8-12] However, to achieve a good signal to noise ratio in reasonably short 
time that would make PAI of deeply-seated lesions practical, the sensitivity of PAI at greater 
tissue depths needs to be improved.[5] Furthermore, many cancers, particularly in their early 
stages, cannot be detected by their intrinsic vascular contrast.[13] These current shortcomings in 
PAI suggest the use of exogenous contrast agents.  
The native light absorption of tissue is wavelength-dependent, with the least absorbance 
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in the NIR region. For instance, the wavelength of maximum penetration of breast tissue is ~725 
nm; whole blood has an absorption minimum at ~710 nm.[14] Thus, using near-infrared 
wavelengths within the ‘spectroscopic window’ (~700-1000 nm) allows tissues to be imaged at 
deeper depth (several cm) than most other optical imaging techniques. It thus follows that a good 
PAI contrast agent ought to have a strong absorption in NIR, particular in the region between 
~700 and 800 nm. Currently, the maximum photoacoustic imaging depth of 8.4 cm have been 
achieved in chicken breast tissue.[47] Internal light delivery has also been proposed to image 
organs beneath the skin.[48] Recently, a dual-modality photoacoustic and ultrasonic imaging 
system to noninvasively detect sentinel lymph nodes based on the accumulation of methylene 
blue dye has been developed.[49] Zackrisson, et al. reviewed the recent advances of 
photoacoustic imaging in biomedical research, and discussed of strategies for clinical translation 
of the PAI technique. Including its use as a noninvasive imaging of the breast, sentinel lymph 
nodes, skin, thyroid, eye, prostate, and ovaries (transvaginal); minimally invasive endoscopic 
imaging of gastrointestinal tract, bladder, and circulating tumor cells (in vivo flow cytometry); 
and intraoperative imaging for assessment of tumor margins and metastases.[50] 
 
The FDA-approved ocular angiographic dye indocyanine green (ICG) and ICG 
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derivatives fulfill this spectroscopic requirement.[15] ICG is confined to the vasculature space 
and it clears rapidly (t1/2 < 3 min), complicating longitudinal in vivo studies. This lead to the 
development of other contrast agents, such as metal-based nanoparticles combined with and 
without organic dyes, nanotubes, and porphyrin-based liposomes.[16-34] Water-soluble 
polydopamine and linear melanin have also been tested as contrast agent for photoacoustic 
imaging with an imaging depth of 12 mm.[51] Since the safety of the use of nanoparticles in 
medicine is unclear so far,[35] it led to the search for novel ways to, for instance, generate dyes 
in tissue.[7, 36, 37] For instance, photoacoustic probes activatable by cancer markers were 
developed.[38, 52] Notably rare from all these reports are novel small molecular dyes as PAI 
contrast agents.[39, 40] 
2-2 Methods and Procedures 
2-2.1 Materials  
The group of Prof. Christian Brueckner in the Department of Chemistry at the University 
of Connecticut has synthesized six free base tetrapyrrolicchromophores, three of which are 
quinoline-annulated porphyrins dyes 1 through 3 prepared from TPP as described in the 
literature,[41] and three morpholinobacteriochlorins dyes 4 through 6 (listed in Figure 2-1) were 
also prepared from TPP as described.[42] These agents exhibit a broad optical absorption 
profiles in the near-infrared window (~700-850 nm) and possess, in comparison to regular 
porphyrins, unusually low fluorescence emission and 1O2 quantum yields. ICG was purchased 
from Sigma Aldrich. The dyes 1 through 3 and ICG were also tested in an aqueous solution using 
the FDA-approved excipient Cremophore EL®, at A = 1.0 at the wavelengths listed in Table 2-2 
at 1 cm and 2 cm path lengths).. The dyes 1 through 6 and ICG were also dissolved in DMF at a 
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concentration so that they possessed all identical absorbances (A = 1.0 at the wavelengths listed 
in Table 2-3 at 1 cm and 2 cm path lengths).  
 
 
Figure 2-1 Structures of the NIR chromophores investigated. 
 
The UV-Vis absorption spectra for all compounds 1 through 6 shown in Figure 2-2 were 
recorded using a Cary 50 spectrophotometer (Varian Analytical Instruments, Walnut Creek, CA). 
The reported results indicate a strong optical absorbance wavelengths between 700 and 900 nm.  
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Figure 2-2 UV-Vis spectra of the chromophores in DMF used in the PAI experiments. The 
concentrations were adjusted to an absorption value of 1.0 0.05 at the respective max wavelength, 1 cm 
glass cuvette. 
The photophysical properties are associated with the molecule energy behavior upon 
absorption of light. The molecular absorbance and emission of light was first described by 
Aleksander Jablonski. In his diagram he explains how electrons are excited from the ground state 
into higher electronic energy states called singlet states, and the events that occur as these excited 
molecules relax by photon emission and other mechanisms to eventually fall back into the 
ground-level energy state. As you can see in Figure 2-3, excited states are short-term, so the 
relaxation back to the ground state happens through emitting fluorescence or thermally emitting 
light quanta through internal conversion (IC). Another possibility that an electron undergo an 
intersystem crossing ISC process transitioning from a singlet state to a triplet state, the relaxation 
from an excited triplet state to the ground singlet state, is either through phosphorescence or, 
through interaction with triplet oxygen (3g), generating singlet oxygen (1g). 
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Figure 2-3 Jablonski diagram: When a molecule absorbs light, it undergo a transition into an excited 
singlet state, from there the system either relaxes back to the ground state through fluorescence or 
thermally through internal conversion (IC).  It can also undergo an inter-system crossing (ISC) into an 
excited triplet state where it relaxes either thermally, through phosphorescence or through interaction with 
triplet oxygen, generating a singlet oxygen. 
Thus, the photophysical parameters such as singlet state lifetime (τS1), the fluorescence 
quantum yield (ΦFluo), the ISC quantum yield (ΦISC), and the singlet oxygen quantum yield (ΦΔ) 
are crucial parameters to assess the relaxation pathways of the chromophores investigated. Some 
of the photophysical properties in Table 2-1 were recorded in collaboration with A. Vollertsen, 
as part of his MS Thesis, Humboldt-University, Berlin, 2012. 
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Table 2-1 Photophysical properties of the dyes investigated 
 max/nm log atmax/ 
cm-1M-1 
Fluo/% ISC/% 
(± 3%) 
n
(± 10%) 
S1/ns 
(± 10%) 
ICG 776,d 794j 5.06 8g 0.6h –i 0.15h 
TPPa 648 3.61 9 (11)c 50 45 0.24 
1k 728 4.30 < 1 2 5 0.04 
2k 726 4.49 < 1 b.d.e < 1 b.d.e 
3m 773 4.44 0.004 –b 4o 0.74, 1.70f 
7k,j 667 3.75 < 1 27 7 1.33 
4k,j 704 4.71 17 45 40 5.40 
5k,j,l 745 4.54 3 85 –b 3.77 
6k,j 790 4.36 0.01 87 12 0.45 
aIn toluene.bNot determined.  c G. H. Barnett, M. F. Hudson, and K. M. Smith, J. Chem. Soc. Perkin 
Trans. I, 1975, 1401-1403.dAt 6.5 µM ICG in H2O, M. L. J. Landsman, G. Kwant, G. A. Mook, W. G. 
Zijlstra, J. Appl. Physiol., 1976, 40, 575–583.  eBelow the detection limit.  f Biexponential decay.  g J. 
Pauli, R. Brehm, M. Spieles, W. A. Kaiser, I. Hilger, and U. Resch-GengerJ. Fluoresc., 2010, 20, 681–
693.  hIn O2-free H2O. T. Luo, MSc Thesis, University of Waterloo, 2008.  
iWhile ICG does not appear to 
generate much, if any, 1O2 upon radiation, it generates medicinally relevant reactive oxygen species: S. 
Fickweiler, R.-M. Szeimies, W. Bäumler, P Steinbach, S. Karrer, A. E. Goetz, C. Abels, and F. 
Hofstädter, J. Photochem. Photobiol. B, 1997, 38, 178–183.jRef. 22.  kmax and log  in CH2Cl2, all else in 
DMF.  l Data for the closely related meso-tetraphenyl derivative.  mmax and log  in CH2Cl2, all else in 
DMSO.  nexcitation = Soret.  
o At excitation = 625 nm, = 21%, a finding rationalized by the presence of 
non-sensitizing dimers that are excited at Soret  
 
 
2-2.2 Photoacoustic System Description 
The PAI system has been designed in our laboratory, which allows connection of any type of 
ultrasound transducer array with a maximum of 64 elements and center frequency scalable with 
the central frequency and bandwidth of the ultrasound transducer between 1 and 10 MHz. The 
two receiving units of 32-channels each amplify channel data independently by 20 dB before 
32:1 multiplexing. Then, the outputs of the two multiplexers are further amplified by two 
independent two-stage variable gain amplifiers and filtered with 0.5-10 MHz band pass filters. 
The total gain of the system is typically set to 60 dB.  The achieved imaging speed of this system 
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in PA mode is 5 frames per second. The system utilizes a unique field programmable gate array 
(FPGA) based reconfigurable processor that allows real-time switching and interlacing between 
the two imaging modalities (i.e. ultrasound and photoacoustic imaging).The system features a 
modular design and the ability of real-time parallel acquisition from 64 channels with each 
channel sampled at 40MHz.[43] 
Photoacoustic images were reconstructed using a typical delay and sum algorithm based 
on the transducer array geometry. These images were then plotted using a color scale. A tunable 
Ti-Sapphire laser (Symphotics TII, LS-2134; Symphotics, Camarillo, CA), optically pumped 
with a Q-switched Nd:YAG laser (Symphotics-TII, LS-2122), operating in the spectral range of 
700nm-1000 nm, was used to illuminate the tubing target with an average power of radiant 
exposure of 18 mJxcm-2, i.e., well below the ANSI limits of 21 mJxcm-2, for the shortest 
wavelengths used.[44] The optical wavelengths used for each dye based on the peak value of the 
UV-Vis absorption data are given in Table 2-3. 
2-2.3 Photoacoustic Phantom Studies  
The feasibility of the porphyrins to serve as PAT contrast agents was tested first using a co-
registering ultrasound and photoacoustic imaging system. Tubing was imaged while injecting 
different porphyrin-based and benchmark (ICG) contrast agents. An Nd:YAG laser set at 745 
nm, 19.0 mW power to illuminate the samples was used. Photoacoustic measurements were 
taken for each sample with a single element ultrasound transducer connected to a Panametrics 
5073PR for amplification and filtering. The dyes have shown enhanced photoacoustic 
measurement over the ICG benchmark used. The monoquinoline-fused dye 3 diluted at 500 
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micro Molar was first used which resulted in 3.7 v signal power, and the bis-quinoline-fused N-
oxide dye 1 diluted at 400 micro Molar resulted in 3.8 v signal power while ICG resulted in 2.02 
v signal power under the same measurement conditions. These results encouraged us to further 
evaluate the PAI signal strengths and compare them to blood and ICG. 
The phantom studies to evaluate the dyes relative to ICG were performed using the set-up 
shown in Figure 2-4. A translucent polyethylene tube with an inner diameter of 0.38 mm and 
outer diameter of 1.09 mm was filled with the standard solutions of the dyes 1 through 6, ICG 
and day-old whole rat blood using a manual syringe. The tube was immersed at 1 and 2 cm 
depths in a tank filled with a 4% intralipid suspension (absorption coefficient µa = 0.01 cm-1, 
reduced scattering coefficient µs’= 4 cm-1.[45] Both ends of the tubing comes out of the tank.  
  
 
 
 
20 
 
 
Figure 2-4 PAI experimental setup. Details: Nd:YAG-pumped tunable Ti:Sapphire laser, average power 
of 18 mJcm-2; ultrasound transducer of central frequency 1.3 MHz and bandwidth of 80%, connected to 
a 64 channel ultrasound PAI system. 
Porphyrin solutions were injected one by one into the tubing and tested, after every 
measurement the tube will be flushed with alcohol twice followed by each injection. The 
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samples are then recollected from the other end of the tube. A different syringe was used for each 
dye to avoid contamination. Upon illumination with an NIR laser tuned to the max of the dye 
investigated (Table 2-3) and spread to 2 cm diameter width at the point where it intersected with 
the tube. The photoacoustic measurements were recorded for each sample solution using a 
commercial low-frequency transducer array (produced by Vermon, France), and consisted of 64 
elements with 0.85 mm pitch. The center frequency of the transducer was 1.3 MHz and 
bandwidth of 80%, connected to a 64 channel ultrasound PAI system. The array was held at 1 
and 2 cm, respectively, away from the center of the intersection of the NIR beam and the tube. 
The signal was then collected and processed by the PAI system. Photoacoustic images were 
reconstructed using a typical ultrasound beam forming algorithm based on the transducer array 
geometry. 
 
2-3 Results and Discussion 
Chromophores 1 through 6 were selected for this investigation because of their UV-Vis NIR 
absorption properties. Their max values (the wavelengths of the band of longest absorption) in 
DMF between 726 nm and 790 nm fall into the spectroscopic window of tissue, and all fall 
within a range of 70 nm of those of ICG in the same solvent as seen in the graph in Figure 2-2, 
allowing for a meaningful direct comparison of the PAI data accrued. Upon light absorption, 
porphyrins generally undergo a ππ* transition into an excited singlet state. From there the 
system either relaxes back to the ground state through fluorescence or thermally through internal 
conversion (IC). It can also undergo an inter-system crossing (ISC) into an excited triplet state. 
In turn, the triplet state relaxes either thermally, through phosphorescence or, frequently 
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observed in porphyrins, through interaction with triplet oxygen (3g), generating singlet oxygen 
(1g). Thus, the singlet state lifetime (τS1), the fluorescence quantum yield (ΦFluo), the ISC 
quantum yield (ΦISC), and the singlet oxygen quantum yield (ΦΔ) are crucial parameters to assess 
the relaxation pathways of the chromophores investigated. 
Two series of experiments were performed. In one, solutions of the dyes 1 through 3 
and ICG in PBS/1% DMF/1% Cremophore EL® were prepared at concentrations that resulted 
all solutions to possess an equal absorption at max (O.D. of 1.0 at 1 cm path length, see 
Figure 2-2), and was irradiated at max. Since all solutions absorbed within a narrow 
window, the energy input difference between the extremes of max is less than 9%. 
Empirically, the data of the PAI experiments was found to vary upon replication by up to 
7%, i.e. the simplification of using different irradiation wavelengths/energies at equal 
absorbance values is within acceptable limits. The phantom studies described below were 
performed, the results of which are listed in Table 2-2. 
Table 2-2 Comparison of the PAI signal strengths in the phantom study 
 irradiation/nm Relative PAI signal 
strength at 1 cm depth 
Relative PAI signal 
strength at 2 cm depth 
ICG 790 1.0 1.0 
1 765 1.6 1.5 
2 755 1.4 1.4 
3 780 1.0 1.1 
To allow a much better direct comparison of the PAI signal strength generated by 
ICG, a blood sample and any given dye, and to allow a correlation to the photophysical data 
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measured primarily in DMF (Table 2-1), a second series of experiments was set up. The 
spectra of the dyes 1 through 6 all overlap with the spectrum of ICG. Thus, DMF solutions of 
the dyes and ICG were prepared and the isoabsorbance point for each dye-ICG pair was 
determined. Then, the concentration of the solutions was adjusted to an O.D. of 1.0 at the 
isoabsorbance wavelength (at 1 cm path length; see Table 2-3 for the irradiation used), thus 
assuring that each ICG-dye pair would receive the identical energy input upon irradiation at 
this wavelength. The blood sample was used as is and irradiated at 750 nm, an arbitrary 
wavelength in the middle of the range of the irradiation used. 
 The phantom studies to evaluate the dyes relative to ICG were performed using the 
set-up shown in Figure 2-4. A translucent polyethylene tube with an inner diameter of 
0.38 mm was filled with the standard DMF solutions of the dyes 1 through 6 and ICG. The 
tube was immersed at 1 and 2 cm depths in a tank filled with a 4% intralipid suspension, a 
white opaque emulsion of soy bean oil, egg phospholipids and glycerin. This emulsion is 
widely used to simulate the scattering properties of biological tissues at wavelengths in the 
red and infrared ranges, where tissue is highly scattering but has a rather low absorption 
coefficient.[45]  
Upon illumination with a NIR laser tuned to the irradiation chosen and spread to 2 cm 
diameter width at the point it intersected with the tube, the photoacoustic measurements were 
recorded for each sample solution using a commercial low-frequency transducer array. The array 
was held at a fixed position 1 cm and 2 cm away from the center of the intersection of the NIR 
beam and the tube, respectively. The PA signal was collected and processed by a PAI system. 
Photoacoustic images were reconstructed using a typical ultrasound beam-forming algorithm 
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based on the transducer array geometry. The data thus obtained were plotted using a color scale, 
providing the photoacoustic images shown in Figure 2-5. The PAI signal strengths relative to 
those obtained for ICG in the same solvents are listed in Table 2-3. 
Table 2-3 Comparison of the PAI signal strengths in the phantom study for dyes 1-6 in solvent DMF 
 irradiation/nm Relative PAI signal 
strength at 1 cm depth 
Relative PAI signal 
strength at 2 cm depth 
ICG 790 1.0 1.0 
blood 750 1.1 1.0 
1 765 2.5 2.4 
2 755 1.9 1.2 
3 780 1.7 1.1 
4 715 Below detection Below detection 
5 765 0.5 0.5 
6 741 0.8 0.7 
 
At 1 cm depth/detector distance, all dyes tested provide a clear image of the target. 
However, the intensity of the signal varied. The signal strengths recorded for the quinoline-
annulated porphyrin 1 through 3 are 1.7 to 2.5-fold stronger than the signal for the benchmark 
compound ICG or the blood sample (that showed very similar PAI signal strengths to those 
obtained with ICG) with compound 1 providing the best signal. The signal strength recorded for 
dye 1 is still nearly 2.4-fold stronger at 2 cm immersion depth/detector distance, though the 
relative advantages of these dyes in DMF over ICG are largely eroded. A comparison of the 
photophysical data for the dyes (Table 2-1) with the PAI data in (Table 2-3) reveals that the best 
PAI contrast agent 1 is mostly differentiated from the other two structurally similar compounds 
(and ICG) by possessing the shortest singlet state lifetime, suggesting that this may have been the 
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crucial factor for its relatively high efficacy.[46] Using an aqueous solvent for the comparison of 
the three dyes with ICG, the absolute signal strength and the relative signal strength advantages 
of the dyes 1 through 3 are not as strong. Given the lower heat capacity of DMF (1.88 JK-1cm-3) 
compared to that of water (4.19 JK-1cm-3) (and ignoring factors such as their varying thermal 
pressure coefficients),[46] the lower light absorption-induced photoacoustic pressure in water 
does not surprise. The fact, however, that the relative drop of the signal strengths with phanton 
immersion depth/detector distance is not as steep when using the aqueous solvent versus DMF, 
does not find a simple explanation. 
As a result of the higher signal-to-noise ratios, the PAI images recorded with dyes 1 and 
2 also show a better-defined tubing structure than the image recorded with ICG (Figure 2-5); 
note that the images shown were recorded using aqueous solvents. The signal strength 
recorded for 3 (no image shown) was identical to that recorded for ICG. However, the  ~4-
fold higher absorptivity of ICG compared to the porphyrinoids at around 750 nm suggest that 
ICG is still a better contrast agent at equal concentrations. As it could be predicted based on 
their higher fluorescence quantum yields, larger ISC yields, longer-lived excited singlet 
states, and higher singlet oxygen quantum yields, the bacteriochlorins 4 through 6 did not 
perform as well as the quinoline-annulated porphyrins or ICG in the PAI experiments. This 
illustrates well the need to fine-tune all photophysical properties of a potential PAI imaging 
dye, not just their optimal absorption properties.  
  
 
 
 
26 
 
 
Figure 2-5 Photoacoustic images of the dyes indicated, dissolved in an aqueous solution containing the 
surfactant Cremophore EL to a concentration resulting in an absorbance value of A = 1.0 at 1 cm path 
lengths. Left column: Targets located at 1 cm depths, right column targets locates at 2 cm depths. Targets: 
a transparent polyethylene tube of inner diameter 0.38 mm and outer diameter 1.09 mm filled with the 
dye solution, submersed in an opaque 4% Intralipid suspension. To best visualize the contrast, the 
dynamic range of the display was set to 10 dB. 
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2-4 Summary 
Direct comparison was performed for a range of porphyrinoids with NIR absorbing properties 
belonging to two different compound classes (quinoline-annulated porphyrins and 
bacteriochlorins) as exogenous PAI imaging contrast agents in phantom studies. Also 
demonstrated the imaging of a sub-mm target at up to 2 cm depth in a tissue-like matrix whereby 
some porphyrinoids matched or exceeded the performance of the benchmark dye ICG at equal 
absorbance or the performance of pure blood. This suggests the use of quinoline-annulated 
porphyrins as potential contrast agents for in vivo use for multi-cm deep tissue PAI. While this 
data does not allow any obvious direct correlations between the photophysical data and the PAI 
contrast enhancement measured to be made, the need for the ability of the dyes to access a very 
efficient thermal relaxation pathway is once again highlighted. Moreover, more members of 
NIR-absorbing porphyrinoids are being screened using a simple and rapid screening tool such as 
the one used here, a direct correlation between the PAI signal strength and key photophysical 
parameters may come into focus, further assisting in the design of optimized contrast agents. The 
best contrast agents identified in this study, the two quinoline-annulated porphyrins, are currently 
undergoing a range of in cyto and in vivo cytotoxicity and PAI studies.   
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Chapter 3 
Dicarboxylic Acid ICG Derivatives Fluorescence Contrast agents 
 
3-1 Introduction 
Tumor hypoxia, defined as an oxygen-deprived condition, has been characterized as 
having detrimental effects on treatment resistance. Hypoxia is a characteristic feature in most 
solid tumors due to the imbalance between new blood vessel formation and rapid proliferation of 
cancer cells. [1-3] The interest in tumor hypoxia has been recognized for more than 60 years.[4] 
Several factors contribute to inadequate oxygen transport and hypoxia, including low vessel 
density and increased oxygen consumption. Angiogenesis promoted by the tissue itself emerges 
as a strategy to meet oxygen demand. However, tumor growth often exceeds the capacity of 
accompanying blood vasculature to deliver adequate quantities of oxygen to the growing cell 
mass.[5-6,41] The development of effective hypoxia probes can help visualize the tumor 
development and would impact the current strategies for early tumor detection and diagnosis in 
improving the outcome of cancer treatment. Additionally, the ability to non-invasively image the 
early events of tumors will enable the tracking of tumor progression and metastases.[7-16,42] 
That is of significant value, specially that this phenomenon begins to emerge when the diameter 
of solid tumor reaches 0.35 mm.[2,40] However, in vivo imaging of the early development of 
tumor remains a great challenge due to the limitations in the sensitivity of current molecular 
imaging probes, delivery of the probes and the interference of intrinsic background signals.[17-
19]  
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A recent review on the biology of hypoxia,[39] indicates that quantification of tumor 
hypoxia can be performed directly or indirectly, and with exogenous or endogenous markers. 
Tumor cells can launch various intracellular signaling pathways to survive hypoxia, such as HIF-
1–mediated gene expression, the unfolded protein response, and AKT-mammalian target of 
rapamycin signaling. These pathways prompt aggressive, metastatic, and treatment-insensitive 
tumors and are considered potential targets for therapy. Hypoxia leads to important, but 
unfortunately not well-understood changes in microRNA expression, epigenetics (study of 
variations that are caused by external factors that switch genes on and off and affect how genes 
being read by cells), and metabolism.  
Near-infrared fluorescence imaging has emerged as a sensitive tool for non-invasive 
cancer imaging,[20-28] and the use of nitroimidazoles as exogenous markers has received great 
attention because of their unique behavior in hypoxic environments owing to their high electron 
affinity. This is a well-studied class of molecular probes that target tumor hypoxia by 
nucleophilic covalent binding to proteins in environments of low pO2 (<1.5% O2).[29-33] A 2-
nitroimidazole-indocyanine green (ICG) conjugate was recently reported to persist in the tumors 
for a significantly longer period than ICG as shown by NIR-fluorescence tomography,[29, 31, 
32, 34-37] suggesting a possible application of the hypoxia selectivity of 2-nitroimidazole family 
for in vivo fluorescence imaging.  
3-1.1 Nitroimidazole-piperazine-ICG 
In an earlier study, the biodistribution of a new generation of hypoxia probe, 2-
nitroimidazole ICG conjugate, with two carbon atoms less in the polyene linker was studied in 
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murine tumor model in vivo. The results were compared with an earlier version of the hypoxia 
probe that was synthesized with an ethanolamine linker. The in vivo experiments were conducted 
with balb/c mice and the new 2-nitroimidazole ICG conjugate showed more than twice the 
average in vivo fluorescence intensity in the tumor beyond two hours post injection as compared 
with the older version of the piperzine-2-nitroimidazole-ICG. These initial results suggested that 
the modified 2-nitroimidazole ICG may significantly improve in vivo tumor hypoxia targeting. 
[43] However, synthesizing 2-nitroimidazole ICG is a very complicated, time-consuming process 
and expensive. In order to overcome these obstacles, 4-nitroimidazole-ICG using piperazine 
linker to conjugate the 4-nitroimidazole and bis-carboxylic acid ICG (4-nitroimidazole-
piperazine-ICG) moieties was synthesized for tumor hypoxia targeting using fluorescence 
imaging. The 4-nitro hypoxia conjugate is easier and considerably cheaper to make compared to 
the 2-nitro probe. The hypoxia targeting performance of the 4-nitroimidazole-piperazine-ICG 
hypoxia probe was compared with the previously tested 2-nitroimidazole-piperazine-ICG and 
imidazole-ICG in tumor bearing mouse model in vivo and data acquired validated the 
performance in vitro in tumor cells. Results with 4-nitroimidazole-piperazine-ICG had shown 
great potential and were had similar results compared to 2-nitroimidazole ICG.   
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3-2 Synthesis of 4-nitroimidazole-ICG Dye Conjugates 
In collaboration with the group of Prof. Michael Smith in the Department of Chemistry at the 
University of Connecticut, 4-nitroimidazole-ICG conjugate has been synthesized using 
piperazine linker to conjugate the 4-nitroimidazole and bis-carboxylic acid ICG (4-
nitroimidazole-piperazine-ICG) moieties. Briefly, the 4-Nitroimidazole (1 g, 8.85 mmol) was 
added to a mixture of methyl bromoacetate (0.84 mL, 8.85 mmol), potassium carbonate (1.8 g, 
13.27 mmol), and TBAI (0.070 g, 0.185 mmol) in 10 ml of acetonitrile. The mixture was heated 
to 80°C, and stirred vigorously at this temperature for 40 min. After cooling the ambient 
temperature, the inorganic salts were removed by vacuum filtration and washed with acetonitrile. 
The filtrate and washings were combined and the solvents evaporated in vacuo to give a residue 
that was recrystallized from ethyl acetate. (1.46 g, 7.87 mmol, 89%).Mp, 129-130°C. 1H NMR 
(DMSO): δ 8.37 (s, 1H), 7.82 (s, 1H), 5.10 (s, 1H); 13C NMR (DMSO): δ 168.5, 147.3, 138.8, 
123.0, 53.0, 48.7. [34] 
UV-Vis absorption and fluorescence spectra for 4-nitroimidazole-ICG in Figure 3-1 
show a maximum absorption peak of 755 nm. The fluorescence spectra were detected with an 
excitation wavelength of 710 nm and had a maximum emission peak at 790 nm. The spectra 
shown were recorded using Varian Cary 50 UV-Vis spectrophotometer. The extinction 
coefficient for the 4-nitroimidazole-ICG conjugate is 207,519 M-1cm-1 and the calculated 
quantum yield is 0.07 as per the procedure discussed in section 1-1.3. 
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Figure 3-1 UV-Vis NIR absorption and fluorescence spectra for 4-nitroimidazole-ICG. 
 
3-3 Methods and Procedures 
3-3.1 In vitro Experiments 
Hypoxia-dependent targeting of the dye was assessed in vitro using 4T1 breast cancer cells. 
Twelve dishes (T7425-2 60 mm x 15 mm surface-modified polystyrene tissue culture dishes (BD 
Falcon, Franklin Lakes, NJ, USA)), each having approximately 1 million tumor cells were 
evaluated. One group of six dishes was exposed to hypoxic conditions (5% CO2, 1% O2, 94% N2, 
37°C) by passing the gas mixture into a hypoxic chamber (Billups-Rothenberg, Inc., Del Mar, 
CA, USA) (Figure 3-2) for 10 min, the gas pressure was maintained at 5 psi throughout the 10 
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min passage and the chamber was then sealed and incubated for 15 h. The gas mixture was 
provided by Airgas East (Cheshire, Connecticut).  
 
Figure 3-2 Hypoxic chamber 
The second group of six dishes was incubated under normoxic conditions (5% CO2, 95% 
O2, 37°C) for the same period.  Two dishes from each group were treated with 3 ml of 15 μM 4-
nitroimidazole-ICG, two other dishes from each group were treated with 3 ml of 15 μM 2-
nitroimidazole-ICG, and two other dishes from each group were treated with 3 ml of 15 μM 
imidazole-ICG. After the injection, the hypoxic group was put back into the hypoxic chamber 
under the same conditions mentioned previously and re-incubated both groups for 9 h. The 
medium was then removed and cells were rinsed with PBS to wash out free compounds and 
immediately both groups were taken for imaging using the Lumina II Imaging System. Cells 
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were then trypsinized to suspend the cells, and 2.5 ml of medium was added to each dish and 
then transferred to a spectroscopic grade cuvette. The fluorescence emission spectra was 
measured for each group using Varian Cary 50 UV-Vis spectrophotometer. 
 
3-3.2 Tumor and Mice Imaging 
In vivo tumor imaging experiments were performed using 4T1 Luc mammary carcinoma cells 
grown in 6-8 week old BALB/c female mice. The animal protocol was approved by the 
Institutional Animal Care and Use Committee of the University of Connecticut. 4T1 cells were 
cultured in 89% DMEM (Dulbecco's Modified Eagle Medium (1X)), 10% FBS (Fetal Bovine 
Serum, (Gibco, USA)) and 1% Pen/Strep (penicillin/streptomycin) and incubated at 37°C with 
5% CO2. The 4T1 breast cancer cells were passed three times at 70% to 80% confluence in a 
T75 flask (BD Biosciences, Bedford, Massachusetts) prior to injection, and 1×10^5 cells were 
administered by subcutaneous injection into the right flank of the mice. The experiments were 
performed when the tumor sizes reached approximately 7-8 mm in diameter. 
Looking at the cultured dishes under the microscope confirms the status of the cultured 
cells visually. In Figure 3-3 are three examples of cultured cells in three different stages, (a) 
Freshly passed cells (b) 70-80% confluence cultured cells and (c) Trypsinized cells (detached).  
  
 
 
 
39 
 
 
Figure 3-3 Cell culture examples 
A group of five mice were injected intravenously through retro-orbital venous sinus with 
100 µl of 4-nitroimidazole-ICG at 25 µM concentration. All injections and imaging experiments 
were done under anesthesia by inhalation of 1.5% isoflurane and 1 L/m O2. While lateral tail 
vein injection could be used for intravascular delivery of agents to mice, this procedure is 
technically challenging and often has a high rate of failure, hence, retro-orbital injection was 
chosen as an easier alternative reliable method for intravascular delivery of agents. Using IVIS 
Lumina II Imaging System (described later), the tumor of each mouse was imaged pre-injection, 
and then imaged for up to 60 min post-injection and then again at 2, 3, 4, 5, 6, 7, 8, 9, 10, 24 and 
48 h. The mice were given a rest from anesthesia every hour. All animals recovered with no 
adversarial effects due to these injections. Fluorescence intensity was averaged and compared. 
After 48 h, mice were euthanized by cervical vertebra dislocation, and six organs including liver, 
spleen, kidneys, lungs, heart and the tumor tissue were excised from the mice. Organs were 
washed twice in PBS before acquiring florescence images for biodistribution analysis. 
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The tumors were imaged using an IVIS® Lumina II Imaging System (Caliper Life 
Sciences, Hopkinton, MA), which can provide visible light photographs and fluorescent images. 
The IVIS Lumina II is capable of imaging both fluorescent and bioluminescent reporters. The 
system is equipped with up to 21 filter sets that can be used to image reporters that emit from 
green to near-infrared. All imaging experiments were performed using a 745 nm excitation filter. 
The Living Image software yields high-quality, reproducible, quantitative results incorporating 
instrument calibration, background subtraction and image region of interest analysis algorithms 
(such as averaging, maximum and minimum, and brightness/contrast adjustment). The unit is 
equipped with gas anesthesia ports and 5 position manifold within imaging chamber allow 
anesthesia to be maintained during imaging sessions. 
3-3.3 Immunohistochemistry (IHC) 
Immunohistochemical staining was performed using the HypoxyprobePlus Kit (FITC-Mab) from 
HPI Inc, to visualize the hypoxia tumor areas using an IHC technique. As recommended by the 
protocol provided by HPI, 45 min before the animal was euthanized, 1.5 mg of 
HypoxyprobePlus Kit diluted in 100 μl of 0.9% saline solution was injected intravenously 
through retro-orbital venous sinus. Immediately after the animal was euthanized, the tumor 
specimens were collected and fast frozen directly in liquid nitrogen until cryosectioned into 10 
μm sections. The prepared sections were stored in −80 °C before staining.  After thawing, the 
sections were fixed in cold acetone for 10 min. Sections were incubated overnight at 4 °C with 
rabbit anti-pimonidazol anti sera PA2627 diluted 1:20 in PBS containing 0.1% bovine serum 
albumin and 0.1% Tween 20. The sections were then incubated for 60 min with FITC-conjugated 
goat anti-rabbit antibody. Between all steps of the staining procedure, the sections were rinsed 
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three times with PBS for 5 min each. Digital images of the stained sections were obtained using 
Zeiss Axio Imager M2 Microscope. The percentage of hypoxic areas was analyzed using the 
ImageJ program (National Institutes of Health, Bethesda, MD, http://rsb.info.nih.gov/ij/). 
 
3-4 Results and Discussion 
3-4.1 In vitro Hypoxia 
The uptake of the dyes by both hypoxic and normoxic tumor cells was examined in culture 
dishes, and compared the results with the putative control imidazole ICG.  All compounds were 
imaged using the Lumina II Imaging System described in the Experimental section. Figure 3-4 
shows one set of three dishes of the hypoxic group marked as (a) dish treated with 15 μM of 
imidazole ICG, (b) dish treated with 15 μM of 2-nitroimidazole-ICG and (c) dish treated with 15 
μM of 4-nitroimidazole-ICG. The average radiant efficiency of the two separate sets was 
measured at 3.61 (±0.32)×107 and 3.27 (±0.30)×107 for 4-nitroimidazole-ICG and 2-
nitroimidazole-ICG, respectively, compared to 1.79 (±0.4)×107 for the control dish of imidazole 
ICG. A graphical representation in Figure 3-5 shows that dishes treated with 2-nitroimidazole-
ICG and 4-nitroimidazole-ICG resulted in the detection of significantly higher levels of 
fluorescence in the cells cultured under hypoxia than those in cells cultured under normoxia 
conditions. The average radiant efficiency of 1.04 (±0.03) ×107 and 1.22 (±0.11) ×107 was 
measured for the 2-nitroimidazole-ICG and 4-nitroimidazole-ICG respectively. Images were 
retrieved using a 745 nm excitation filter. These results were encouraging to further study the 
efficacy of this probe attachment to hypoxic regions in vivo which will be discussed in the next 
chapter. 
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Figure 3-4 Fluorescence images of cultured 4T1 breast cancer cells under hypoxic conditions treated with 
(a) imidazole ICG, (b) 2-nitroimidazole-ICG, and (c) 4-nitroimidazole-ICG 
 
  
Figure 3-5 Graphical bars show average radiant efficiency of the hypoxic and normoxic dishes of the 
imidazole ICG (5), 2-nitroimidazole-ICG (4), and 4-nitroimidazole-ICG (6). 
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3-4.2 In vivo Imaging 
Fluorescent images in Figure 3-6 was taken using the IVIS® Lumina II Imaging System of the 
whole mouse body imaging over time (48 h) showing the accumulated uptake of the injected (A) 
4-nitroimidazole-ICG, (B) 2-nitroimidazole-ICG and (C) Imidazole-ICG. The imaging system 
was set at a 745 nm excitation filter. Fluorescence radiation started to appear at one minute after 
injection and the radiant efficiency (Radiant efficiency, unit: p/sec/cm2/sr/(µW/cm2)) plateaued 
at 15 min post-injection. As Figure 3-6 (A) shows, injection with 4-nitroimidazole-ICG persisted 
for 48 hours and a residual trace was shown at 48 hours post injection which compared to 2-
nitroimidazole-ICG injection on average performed even better as seen in (B). While imidazole-
ICG stayed in mice for about three hours and was washed away (C). The data was collected for 
the maximum radiation efficiency throughout the 48 h was quantitatively evaluated and 
expressed as the mean fluorescence signal (±sd), then compared to same concentration injection 
of 2-nitroimidazole-ICG and imidazole-ICG under the same conditions. 
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(A)  
(B)  
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(C)  
Figure 3-6 In vivo fluorescence distribution of a mouse injected with 100 µl at 25 µM concentration of 
(A) 4-nitroimidazole-ICG (B) 2-nitroimidazole-ICG and (C) Imidazole-ICG. (Image on top left is pre-
injection and at 1, 5, 15, 30 min, 1 through 10 h, 24 and 48 h post-injection). 
Table 3-1 and the graphical representation in Figure 3-7 show the dye washout as a 
function of time comparing the three groups of nitroimidazole conjugates; the 4-nitroimidazole-
ICG shows a higher fluorescent intensity with an uptake at about 1.5-fold over 2-nitroimidazole-
ICG and about 2.5-fold over the imidazole-ICG at the 15 min peak post-injection. Maximum 
radiant efficiency for 4-nitroimidazole-ICG, 2-nitroimidazole-ICG and imidazole-ICG was 
measured at 5.05 (±0.57) ×109, 3.39 (±0.33) ×109 and 2.00 (±0.20) ×109 respectively. Strong 
fluorescence intensity was still detected 3 hours post-injection at 91 and 69 times higher than the 
background for the 4-nitroimidazole-ICG and 2-nitroimidazole-ICG compared to 25 times for 
imidazole-ICG.  
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Based on these results, the efficacy of 4-nitroimidazole-ICG as a hypoxia targeting 
fluorescence probe has been proven to be effective and the dye was retained to a great extent in 
hypoxic tumors when compared with imidazole ICG derivative. 
Comparisons between multiple groups were made with two-way ANOVA analyses. 
When comparing the radiation intensity between the three different conjugates using two-tail t-
test, 4-nitrioimidazole-ICG was shown to have a slightly higher intensity than 2-nitrioimidazole-
ICG. However, this increase was not statistically significant (p > 0.05). On the other hand, 4-
nitroimidazole-ICG was shown to have a statistically significant increase in intensity when 
compared to imidazole-ICG, (p < 0.05).  
Table 3-1 Radiant efficiency of the dye conjugates 
Time 
4 nitroimidazole-pip 
(x10
9
) 
2 nitroimidazole-pip 
(x10
9
) 
imidazole ICG 
(x10
9
) 
Background 0.009 (±0.001) 0.009 (±0.0004) 0.013 (±0.0014) 
1 min 3.72 (±0.27) 1.57 (±0.18) 1.14 (±0.003) 
15 min 5.05 (±0.57) 3.39 (±0.33) 2.00 (±0.20) 
1 h 3.80 (±0.79) 2.95 (±0.46) 0.717 (±0.11) 
3 h 0.84 (±0.28) 0.643 (±0.16) 0.347 (±0.21) 
6 h 0.39 (±0.16) 0.295 (±0.06) 0.202 (±0.17) 
9 h 0.29 (±0.09) 0.237 (±0.06) 0.0874 (±0.01) 
24 h 0.17 (±0.08) 0.130 (±0.02) 0.0677 (±0.03) 
48 h 0.1 (±0.05) 0.0971 (±0.02) 0.0486 (±0.02) 
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Figure 3-7 A graphical representation showing the washout as a function of time comparing the three 
groups of nitroimidazole conjugates, the 4-nitroimidazole-ICG shows a higher fluorescent intensity after 
15 min post-injection. 
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3-4.3 Biodistribution Analysis 
For dye accumulation and retention analysis in organs, mice were euthanized 48 h post-injection, 
and six organs were excised and imaged. Fluorescence intensity of tumor, heart, lungs, kidneys, 
spleen and liver were measured. Figure 3-8 shows the average fluorescence intensity distribution 
in the organs calculated from all mice groups injected with 4-nitroimidazole-ICG, 2-
nitroimidazole-ICG and imidazole-ICG, and results show a high retention in tumor and kidneys 
in both 4-nitroimidazole-ICG and 2-nitroimidazole-ICG due to slow loss of the dye conjugates 
from the tumor as a function of time with excretion via the kidney and liver. The mean value 
measured for maximum fluorescence intensity in tumor was 1.39 (±0.44) ×108 for the group 
injected with 4-nitroimidazole-ICG and 1.8 (±0.77) ×108 for the group injected with 2-
nitroimidazole-ICG, these results are still two times higher than the imidazole-ICG which is in 
agreement with the in vivo measurements. Figure 3-9 shows the fluorescence images of the 
major organs and tumor for the mice group injected with 4-nitroimidazole-ICG at 48 h (2-
nitrioimidazole-ICG and imidazole-ICG images not shown). Using a two-tail t-test was 
performed between 4-nitrioimidazole-ICG and 2-nitrioimidazole-ICG ex vivo data groups and in 
agreement with our in-vivo data, there was no significant difference statistically (p > 0.05).   
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Figure 3-8 Biodistribution analysis of all mice groups bearing 4T1 tumors after retro-orbital venous sinus 
with 100 µl of 4-nitroimidazole-ICG, 2-nitroimidazole-ICG and imidazole-ICG. Bars represent the 
retention of the dye 48 h post-injection. 
 
Figure 3-9 Fluorescence images show major organs and tumor for the mice group injected with 4-
nitroimidazole-ICG at 48 h. 
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3-4.4 Immunohistochemistry 
To determine the hypoxic status in various tumor groups, we obtained histology images of 
stained sections using Zeiss Axio Imager M2 microscope; images were analyzed using ImageJ to 
calculate the percentage of the hypoxic area. The percentage of the hypoxic area is defined as the 
number of pixels above the threshold in hypoxic areas, over the total number of pixels of the 
total area analyzed. We prepared four stained sections of each tumor. The average hypoxic area 
percentage from mice treated with 2-nitroimidazole-ICG, 4-nitroimidazole-ICG, and imidazole 
ICG was calculated at 1.6% (±0.011), 2.7% (±0.019) and 3% (±0.022) respectively. A 
representation of the data analysis is shown in Figure 3-10. These results show no statistical 
significant difference of hypoxic area percentage between the 4-nitroimidazole-ICG and 2-
nitroimidazole-ICG (p > 0.05) and similarly 4-nitroimidazole-ICG and imidazole ICG hypoxic 
area percentage also showed no statistical significant difference (p > 0.05). 
 
Figure 3-10 Averaged hypoxic area percentage calculated on all stained tumor slices (sectioned at 10μm) 
referenced as 2-nitroimidazole-ICG (4), 4-nitroimidazole-ICG (6), and imidazole ICG (5) 
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To validate differences in dye residual accumulation in each tumor, fluorescence images 
were obtained from commercial Li-COR imaging system and they are shown in Figure 3-11, 
with mice injected with (a) 2-nitroimidazole-ICG, (b) 4-nitroimidazole-ICG, and (c) imidazole 
ICG.  Using ImageJ software, the average integrated fluorescence density over the tumor sample 
area was calculated and mean value of the four different slices in each group was measured at 
54.3 (±10.1) and 50.6 (±9.8) for 2-nitroimidazole-ICG and 4-nitroimidazole-ICG, respectively, 
compared to 8.5 (±3.1) for imidazole ICG as shown in Figure 3-12. These results indicate 
similar fluorescence properties for both 4-nitroimidazole-ICG and 2-nitroimidazole-ICG.  The 
difference of tumor-integrated density between 4-nitroimidazole-ICG and 2-nitroimidazole-ICG 
was not statistically significant (p > 0.05). However, significant difference was observed 
between 4-nitroimidazole-ICG and imidazole ICG (p < 0.05). This data confirms our ex vivo 
study and confirm dye residual in the tumor area. 
 
Figure 3-11 Li-COR images of 10 μm slices of mice tumors injected with (a) 2-nitroimidazole-ICG (4) 
(b) 4-nitroimidazole-ICG (6), and (c) imidazole ICG (5) 
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Figure 3-12 A graphical representation showing the average integrated density calculated for all stained 
slices imaged with Li-COR imager. 
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3-5 Summary 
The results presented here demonstrate the feasibility of using the 4-nitroimidazole-ICG as a 
hypoxia targeting fluorescence probe. Despite the fact that 2-nitro derivatives have been shown 
to be the more useful derivatives for NIR fluorescence imaging of hypoxic tumors, the efficacy 
of 4-nitroimidazole-ICG as a hypoxia targeting fluorescence probe has been demonstrated.  Li-
COR imaging data analysis confirmed very similar fluorescence properties 4-nitroimidazole-ICG 
and 2-nitroimidazole-ICG.  Analysis of data collected from tumor cells as well as that from the 
moue studies showed that both dye-conjugates were retained to a great extent in hypoxic tumors 
when compared with imidazole derivative, which is taken to be a realistic standard to probe the 
efficacy of each dye.  However, the retention of the imidazole derivative in the tumors suggests 
that other factors are at work for uptake of the dye conjugates by the tumor.  Further studies are 
required to illuminate this issue.  The histology images of tumor stained sections confirm similar 
hypoxic condition of three mice groups.  
Currently, 2-nitroimidizole sells for about $343.50/g whereas 4-nitroimidazole for 
$1.81/g, so the 2-nitroimdiazole is nearly 190 times as expensive on a per-gram basis [44]. The 
cost of 2-nitroimidazole is, therefore, nearly prohibitive for scale-up of the multi-step synthesis 
of our dye-conjugates. Based on price considerations alone, the preparation of a 4-nitroimidazole 
dye-conjugate was a worthy goal. However, there are concerns about the toxicity of 4-
nitroimidazole derivatives as reported in earlier work. [45-46] Despite these reports, work by 
Wang and coworkers [47] as well as Zhang, Jin, and coworkers [48] showed that the preparation 
of 99mTc-labeled 4-nitroimidazole complexes for imaging tumor hypoxia was feasible, and they 
reported positive results. 
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A cytotoxicity was not performed at this current work, but it is would be required if 4-
nitroimidazole-piperazine-ICG is to be pursed as a useful imaging agent. However, no 
observable difference for the mice injected with either of the three dyes based on post-injection 
activity or weight loss, suggesting that there is no significant short-term toxicity was noticed. 
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